{"id":615563,"date":"2022-09-09T19:04:01","date_gmt":"2022-09-09T19:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=615563"},"modified":"2022-09-09T19:04:01","modified_gmt":"2022-09-09T19:04:01","slug":"homozygous-familial-hypercholesterolemia-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/homozygous-familial-hypercholesterolemia-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_615563.html","title":{"rendered":"Homozygous Familial Hypercholesterolemia Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"
\n
\"Homozygous<\/a><\/div>\n
\n
Homozygous Familial Hypercholesterolemia Pipeline<\/div>\n<\/div>\n<\/div>\n
Homozygous Familial Hypercholesterolemia pipeline constitutes 3+ key companies continuously working towards developing 3+ Homozygous Familial Hypercholesterolemia treatment therapies, analyzes DelveInsight<\/div>\n

Homozygous familial hypercholesterolaemia<\/strong> (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD).<\/p>\n

 <\/p>\n

“Homozygous Familial Hypercholesterolemia Pipeline Insight, 2022”<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Homozygous Familial Hypercholesterolemia Market. <\/p>\n

The Homozygous Familial Hypercholesterolemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

 <\/p>\n

To know more about the Homozygous Familial Hypercholesterolemia Pipeline Report, click here: Homozygous Familial Hypercholesterolemia Pipeline Insights<\/a><\/strong><\/p>\n

 <\/p>\n

DelveInsight’s Homozygous Familial Hypercholesterolemia Report covers around 3+ products under different phases of clinical development like<\/strong><\/p>\n

• Late-stage Homozygous Familial Hypercholesterolemia products (Phase III)<\/p>\n

• Mid-stage Homozygous Familial Hypercholesterolemia products (Phase II)<\/p>\n

• Early-stage Homozygous Familial Hypercholesterolemia product (Phase I)<\/p>\n

• Pre-clinical and Discovery stage candidates<\/p>\n

• Discontinued & Inactive candidates<\/p>\n

• Homozygous Familial Hypercholesterolemia Route of Administration<\/p>\n

 <\/p>\n

Emerging Homozygous Familial Hypercholesterolemia Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n

• ARO-ANG 3: Arrowhead Pharmaceuticals<\/p>\n

• Tafolecimab: Innovent Biologics<\/p>\n

And Many Others<\/p>\n

 <\/p>\n

Further Homozygous Familial Hypercholesterolemia product details are provided in the report. Download the Homozygous Familial Hypercholesterolemia pipeline report to learn more about the emerging Homozygous Familial Hypercholesterolemia therapies at: Homozygous Familial Hypercholesterolemia Clinical Trials Advancements<\/a><\/strong><\/p>\n

 <\/p>\n

Homozygous Familial Hypercholesterolemia Pipeline Analysis<\/strong><\/p>\n

The Homozygous Familial Hypercholesterolemia report provides insights into: <\/strong><\/p>\n